Literature DB >> 31280574

Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma.

Veronica Mollica1, Vincenzo Di Nunno1, Francesco Massari2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31280574     DOI: 10.21037/cco.2019.04.05

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


× No keyword cloud information.
  9 in total

Review 1.  Tumor vessel normalization and immunotherapy in gastric cancer.

Authors:  Xianzhe Yu; Shan He; Jian Shen; Qiushi Huang; Peng Yang; Lin Huang; Dan Pu; Li Wang; Lu Li; Jinghua Liu; Zelong Liu; Lingling Zhu
Journal:  Ther Adv Med Oncol       Date:  2022-07-18       Impact factor: 5.485

2.  Expression of VEGF, CD73 and their relationship with clinical pathology, microvessel density, and prognosis in renal cell carcinoma.

Authors:  Xuefeng Mei; Jia Shu; Ruizhen Huang; Xin Chu; Ying Tian
Journal:  Transl Androl Urol       Date:  2020-06

3.  Comprehensive analysis of glutathione peroxidase-1 (GPX1) expression and prognostic value in three different types of renal cell carcinoma.

Authors:  Shaohua Chen; Xiaotao Su; Hua Mi; Xiaodi Dai; Songheng Li; Shaoyong Chen; Siqin Zhang
Journal:  Transl Androl Urol       Date:  2020-12

Review 4.  The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review.

Authors:  Qinghong Wei; Hongmei He; Long Lv; Xiaoying Xu; Weibing Sun
Journal:  Transl Androl Urol       Date:  2020-12

5.  Expression and clinical significance of NUF2 in kidney renal clear cell carcinoma.

Authors:  Li Shan; Xiao-Li Zhu; Yuan Zhang; Guo-Jian Gu; Xu Cheng
Journal:  Transl Androl Urol       Date:  2021-09

6.  MiRNA-124 regulates the sensitivity of renal cancer cells to cisplatin-induced necroptosis by targeting the CAPN4-CNOT3 axis.

Authors:  Qingyan Mao; Qianfeng Zhuang; Jie Shen; Zhen Chen; Dong Xue; Tao Ding; Xiaozhou He
Journal:  Transl Androl Urol       Date:  2021-09

7.  Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.

Authors:  Dylan J Martini; T Anders Olsen; Subir Goyal; Yuan Liu; Sean T Evans; Emilie Elise Hitron; Greta Anne Russler; Lauren Yantorni; Sarah Caulfield; Jacqueline T Brown; Jamie M Goldman; Bassel Nazha; Bradley C Carthon; Wayne B Harris; Omer Kucuk; Viraj A Master; Mehmet Asim Bilen
Journal:  J Immunother Precis Oncol       Date:  2022-06-14

8.  ACO1 and IREB2 downregulation confer poor prognosis and correlate with autophagy-related ferroptosis and immune infiltration in KIRC.

Authors:  Ting Zhu; Zhuoyu Xiao; Haoyu Yuan; Hu Tian; Taoyi Chen; Qi Chen; Mingkun Chen; Jiankun Yang; Qizhao Zhou; Wenbin Guo; Kangyi Xue; Ming Xia; Jiming Bao; Cheng Yang; Haifeng Duan; Hongyi Wang; Zhipeng Huang; Cundong Liu; Junhao Zhou
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

9.  Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis.

Authors:  Linna Shi; Ruihua Lv; Chen Li; Dong Han; Zhanli Ren; Ge Ren
Journal:  Transl Androl Urol       Date:  2020-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.